As pioneers and leaders in understanding the interaction of light and human biology, CLINUVEL’s products have been developed after years of extensive scientific research and understanding of rare disorders.

Our products have been developed to address previously neglected patient populations, and we take pride in improving the quality of life of others.

CLINUVEL’s lead product, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been granted marketing authorisation by the European Commission for the prevention of phototoxicity in adult patients with EPP. Click here to read more.
In June 2018 CLINUVEL submitted a new drug application with the US FDA seeking marketing authorisation for SCENESSE®. Click here to read more.

For more information on CLINUVEL’s pipeline click here